BFRI
Biofrontera Inc.Company Information
- Company Name
- Biofrontera Inc.
- CIK
- CIK0001858685
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- BFRI: Nasdaq, BFRIW: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- BFRI
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- —
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 2,708,191
- Shares outstanding
- 12,923,710
- Ownership
- 20.96%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 27.78%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 5 | 6 | 6 | 3 | 7 | 2 | 6 | 3 | 4 | 4 | 1 | 3 | ||||||
| Equity Securities Fv Ni | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | ||||||
| Accounts Receivable Net Current | 6 | 4 | 7 | 3 | 4 | 4 | 5 | 5 | 4 | 4 | 5 | 4 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 12 | 13 | 18 | 14 | 19 | 15 | 21 | 17 | 17 | 20 | 23 | 30 | ||||||
| Inventory Net | 1 | 1 | 1 | 4 | 4 | 7 | 7 | 7 | 4 | 7 | 11 | 16 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 2 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | ||||||
| Assets Held For Sale Not Part Of Disposal Group Current | - | - | - | 2 | 2 | 2 | 2 | 2 | - | - | - | - | ||||||
| Inventory Noncurrent | 4 | 4 | 4 | - | - | - | - | - | - | - | - | - | ||||||
| Property Plant And Equipment Net | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 3 | 3 | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | ||||||
| Intangible Assets Net Excluding Goodwill | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 3 | 3 | ||||||
| Other Assets | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 24 | 25 | 29 | 15 | 20 | 17 | 22 | 19 | 22 | 25 | 28 | 34 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Business Combination Contingent Consideration Liability Current | - | - | - | - | - | - | - | - | - | - | - | 7 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 11 | 11 | 12 | 13 | 20 | 11 | 12 | 11 | 9 | 14 | 18 | 29 | ||||||
| Operating Lease Liability Current | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Accounts Payable And Other Accrued Liabilities Current | 5 | 5 | 5 | 7 | 6 | 5 | 4 | 5 | 4 | 4 | 4 | 11 | ||||||
| Lines Of Credit Current | - | - | - | - | - | - | - | - | - | - | - | 2 | ||||||
| Short Term Borrowings | - | - | - | - | - | - | - | - | 0 | 2 | 4 | - | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Business Combination Contingent Consideration Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 3 | ||||||
| Convertible Notes Payable | 5 | 5 | 5 | 4 | 4 | 4 | 4 | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 18 | 19 | 18 | 18 | 25 | 16 | 18 | 13 | 11 | 26 | 23 | 33 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital | 139 | 139 | 138 | 131 | 122 | 122 | 122 | 122 | 121 | 105 | 104 | 104 | ||||||
| Stockholders Equity | 6 | 6 | 10 | -3 | -5 | 0 | 4 | 6 | 11 | -5 | 5 | 1 | ||||||
| Retained Earnings Accumulated Deficit | -133 | -133 | -128 | -134 | -127 | -122 | -117 | -116 | -110 | -110 | -100 | -103 | ||||||
| Liabilities And Stockholders Equity | 24 | 25 | 29 | 15 | 20 | 17 | 22 | 19 | 22 | 25 | 28 | 34 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | - | - | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 20 | 20 | 20 | 20 | 20 | - | 20 | - | - | 20 | 20 | 20 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 70 | 70 | 70 | 70 | 70 | 35 | 70 | 35 | 35 | 35 | 35 | 15 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Common Stock Shares Issued | 14 | 12 | 12 | 12 | 10 | 9 | 9 | 7 | 5 | 5 | 2 | 1 | ||||||
| Shares Outstanding | 14 | 12 | 12 | 12 | 10 | 9 | 9 | 7 | 5 | 5 | 2 | 1 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBiofrontera Inc. (BFRI) — SEC Financial Statements & Analysis
Biofrontera Inc. (BFRI) is a pharmaceutical preparations company, incorporated in DE. Biofrontera Inc. trades on Nasdaq as: BFRI, BFRIW. Biofrontera Inc. (BFRI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Biofrontera Inc. carries a market cap of $12.23M, a P/E ratio of -1.92x, a P/B ratio of 2.05x, a P/S ratio of 0.26x, an enterprise value of $7.57M, and an EV/EBITDA multiple of -1.18x. On profitability, it posts a gross margin of 81.22%, an operating margin of -14.22%, a net margin of -13.78%, a Return on Equity (ROE) of -988.35%, a Return on Assets (ROA) of -28.80%, and a Return on Invested Capital (ROIC) of -36486.22%. Per share, it reports EPS of $-0.49, diluted EPS of $-0.49, free cash flow per share of $-0.61, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 17.83% year-over-year, net income growth of -61.64% year-over-year, and EPS growth of -72.24% year-over-year. On the balance sheet, it maintains a current ratio of 1.18x, a quick ratio of 0.99x, working capital of $1.89M, a debt-to-equity ratio of 3.04x, a debt ratio of 0.75, an interest coverage ratio of -13.62x, free cash flow of $-7.93M (TTM), and net debt of $-4.66M. Figures sourced from SEC EDGAR.
- Market Cap
- $12.23M
- P/E TTM
- -1.92x
- EPS TTM
- $-0.49
- P/B TTM
- 2.05x
- ROE TTM
- -988.35%
- ROA TTM
- -28.80%
- Debt To Equity
- 3.04x
- Free Cash Flow TTM
- $-7.93M
- Net Revenue TTM Growth 1Y
- 17.83%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Biofrontera Inc. in?
Biofrontera Inc. (BFRI) operates in the Pharmaceutical Preparations industry.
What exchange does BFRI trade on?
Biofrontera Inc. (BFRI) trades on the Nasdaq.
Where is Biofrontera Inc. incorporated?
Biofrontera Inc. is incorporated in DE.
When was Biofrontera Inc. (BFRI)'s most recent SEC filing?
Biofrontera Inc. (BFRI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is BFRI's market cap?
Biofrontera Inc. (BFRI) has a market capitalization of $12.23M as of 2026-06-30.
What is BFRI's EPS (earnings per share)?
Biofrontera Inc. (BFRI)'s trailing twelve month EPS is $-0.49 as of 2026-06-30.
What is BFRI's ROE (return on equity)?
Biofrontera Inc. (BFRI)'s trailing twelve month Return on Equity (ROE) is -988.35% as of 2026-06-30.
What is BFRI's ROA (return on assets)?
Biofrontera Inc. (BFRI)'s trailing twelve month Return on Assets (ROA) is -28.80% as of 2026-06-30.
What is BFRI's ROIC (return on invested capital)?
Biofrontera Inc. (BFRI)'s trailing twelve month Return on Invested Capital (ROIC) is -36486.22% as of 2026-03-31.
What is BFRI's EV/EBITDA?
Biofrontera Inc. (BFRI)'s trailing twelve month EV/EBITDA is -1.18x as of 2026-06-30.